USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination.

ABSTRACT:

Background/aims

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression.

Methods

USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes.

Results

USP29 protein levels were significantly reduced in mice and humans with

SUBMITTER: Hu S 

PROVIDER: S-EPMC11791544 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature